Spirobarbital
From Wikipedia, the free encyclopedia
Jump to: navigation, search
![]() |
|
Systematic (IUPAC) name | |
---|---|
1-ethyl-2,4-dimethyl-7,9-diazaspiro[4.5]decane-6,8,10-trione
|
|
Identifiers | |
CAS Number | 12262-77-0 ![]() |
ATC code | none |
UNII | LR477QH2IL ![]() |
Synonyms | 5-spiro-(2'-ethyl-3'-5'-dimethyl-cyclopentyl)barbituric acid |
Chemical data | |
Formula | C12H18N2O3 |
Molar mass | 238.282 g/mol |
3D model (Jmol) | Interactive image |
|
|
(verify) |
Spirobarbital is a barbiturate derivative developed by Eli Lilly in the 1940s.[1] It has hypnotic and sedative effects, and has a moderate potential for abuse.[2]
References[edit]
- ^ US Patent 2561688
- ^ Isbell H, Chrusciel TS. Dependence Liability of Non-Narcotic Drugs. Bulletin of the World Health Organisation 1970; 43: Supplement.
Alcohols | |
---|---|
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents | |
Monoureides | |
Neuroactive steroids |
|
Nonbenzodiazepines |
|
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: GABAergics
|
![]() |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |